摘要
有效治疗痴呆症,如阿尔茨海默氏病(阿尔茨海默病)的前景是渺小的,由于其破坏了关键的高级认知功能的背后的脑途径。有一个重大的转变,在该领域的检测条件,如AD,在他们的最早阶段,这将允许预防或治疗方法,大大降低风险和/或减缓疾病的进展。AD的特点是标志性的病理改变,如胞外Aβ斑块和细胞内神经原纤维病理,选择性地影响神经元和大脑回路的特定子类。目前的证据表明, 在显性痴呆前Aβ 斑块开始用许多年形成,渐进的病理学,提供了一个潜在的早期干预的目标。早期的在大脑中Aβ的变化导致局部损伤树突,对兴奋性突触和投射神经元的过程极易受到攻击。Aβ病理学是一系列的转基因模型中过度表达突变的人类家族性AD的基因复制(如APP、早老素1)。研究与β斑块相关神经炎过程异常再生和退行性改变的发展可能是了解AD和神经元损伤的病理特征之间的关系的最好方式,并制定早期预防、延缓或减轻对Aβ病理和/或导致认知功能障碍的神经改变。
关键词: 阿尔茨海默病,淀粉样前体蛋白,Aß,血小板,营养不良的神经轴突,选择性易损性,转基因小鼠。
Current Alzheimer Research
Title:Defining the earliest pathological changes of Alzheimer’s disease
Volume: 13 Issue: 3
Author(s): James C. Vickers, Stan Mitew, Adele Woodhouse, Carmen M. Fernandez-Martos, Mathew T. Kirkcaldie, Alison J. Canty and Graeme H. McCormack, Anna E. King
Affiliation:
关键词: 阿尔茨海默病,淀粉样前体蛋白,Aß,血小板,营养不良的神经轴突,选择性易损性,转基因小鼠。
摘要: The prospects for effectively treating well-established dementia, such as Alzheimer’s disease (AD), are slim, due to the destruction of key brain pathways that underlie higher cognitive function. There has been a substantial shift in the field towards detecting conditions such as AD in their earliest stages, which would allow preventative or therapeutic approaches to substantially reduce risk and/or slow the progression of disease. AD is characterized by hallmark pathological changes such as extracellular Aβ plaques and intracellular neurofibrillary pathology, which selectively affect specific subclasses of neurons and brain circuits. Current evidence indicates that Aβ plaques begin to form many years before overt dementia, a gradual and progressive pathology which offers a potential target for early intervention. Early Aβ changes in the brain result in localized damage to dendrites, axonal processes and synapses, to which excitatory synapses and the processes of projection neurons are highly vulnerable. Aβ pathology is replicated in a range of transgenic models overexpressing mutant human familial AD genes (eg APP and presenilin 1). Studying the development of aberrant regenerative and degenerative changes in neuritic processes associated with Aβ plaques may represent the best opportunity to understand the relationship between the pathological hallmarks of AD and neuronal damage, and to develop early interventions to prevent, slow down or mitigate against Aβ pathology and/or the neuronal alterations that leads to cognitive impairment.
Export Options
About this article
Cite this article as:
James C. Vickers, Stan Mitew, Adele Woodhouse, Carmen M. Fernandez-Martos, Mathew T. Kirkcaldie, Alison J. Canty and Graeme H. McCormack, Anna E. King , Defining the earliest pathological changes of Alzheimer’s disease , Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/1567205013666151218150322
DOI https://dx.doi.org/10.2174/1567205013666151218150322 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Regenerative Medicine Neuromodulation of Hippocampal Synaptic Plasticity, Learning, and Memory by Noradrenaline
Central Nervous System Agents in Medicinal Chemistry Effects of ACE Inhibitors on Skeletal Muscle
Current Pharmaceutical Design Generation and Transplantation of Dopaminergic Neurons Derived from Embryonic Stem Cells
Current Stem Cell Research & Therapy Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Hyper-Homocysteinemia Alters Amyloid Peptide-Clusterin Interactions and Neuroglial Network Morphology and Function in the Caudate After Intrastriatal Injection of Amyloid Peptides
Current Alzheimer Research Non-Coding RNA in Brain Development and Disorder
Current Medicinal Chemistry Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology Cocaine and HIV-1 Interplay in CNS: Cellular and Molecular Mechanisms
Current HIV Research Possible Role of Vascular Risk Factors in Alzheimer's Disease and Vascular Dementia
Current Pharmaceutical Design Preface [Hot topic: Protein Misfolding in the Amyloidoses and other Disorders (Guest Editor: David R. Howlett)]
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology The Indiana Alzheimer Disease Centers Symposium on Mild Cognitive Impairment. Cognitive Training in Older Adults: Lessons from the ACTIVE Study
Current Alzheimer Research Cognitive Dysfunction in Depression: Lessons Learned from Animal Models
CNS & Neurological Disorders - Drug Targets Vascular Inflammation in Cardiovascular Disease: Is Immune System Protective or Bystander?
Current Pharmaceutical Design No Significant Effect of 7,8-Dihydroxyflavone on APP Processing and Alzheimer-Associated Phenotypes
Current Alzheimer Research Cytosolic Phospholipase A2 Inhibitors as Therapeutic Agents for Neural Cell Injury
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents BACE Inhibitors as Potential Therapeutics for Alzheimers disease
Recent Patents on CNS Drug Discovery (Discontinued) Patented In Vitro Blood-Brain Barrier Models in CNS Drug Discovery
Recent Patents on CNS Drug Discovery (Discontinued) Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets